REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

This study tests a new drug called BGB-21447 for people with certain blood cancers (like lymphoma and leukemia) that have returned or not improved after prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors. About 112 participants will re…

This study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the drugs work toget…

This study tests whether giving duvelisib on an irregular schedule can still control chronic lymphocytic leukemia or small lymphocytic lymphoma while causing fewer severe side effects. Fifteen adults with cancer that has come back or not responded to treatment will take part. The…

This study tests a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see how many patients achieve complete remission after 24 cycles of treatment. The trial includ…

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…

This study tested a combination of two targeted drugs, venetoclax and ibrutinib, in 234 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal was to see how well the drugs control the cancer, especially in patients whose disease came back or had h…

This early-stage trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogn…

This early-phase study tests a combination of three drugs (lenalidomide, ibrutinib, and rituximab) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatment. The main goal is to find the safest dose…

This early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…